Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)

被引：9

作者：

Halland, Nis ^{[1
]}

Czech, Joerg ^{[1
]}

Czechtizky, Werngard ^{[1
]}

Evers, Andreas ^{[1
]}

Follmann, Markus ^{[1
,2
]}

Kohlmann, Markus ^{[1
]}

Schreuder, Herman A. ^{[1
]}

Kallus, Christopher ^{[1
,3
]}

机构：

[1] Sanofi R&D, Ind Pk Hochst Bldg G838, D-65926 Frankfurt, Germany

[2] Bayer Pharma AG, Aprather Weg 18A, D-42113 Wuppertal, Germany

[3] Bayer Cropsci, Ind Pk Hochst Bldg G836, D-65926 Frankfurt, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2016年 / 59卷 / 20期

关键词：

PROCARBOXYPEPTIDASE-B; CARBOXYPEPTIDASE-N; ARGININE; PLASMA; TARGET; STATE;

D O I：

10.1021/acs.jmedchem.6b01276

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Previously disclosed TAFIa inhibitors having a urea zinc-binding motif were used as the starting point for the development of a novel class of highly potent inhibitors having a sulfamide zinc-binding motif. High-resolution X-ray cocrystal structures were used to optimize the structures and reveal a highly unusual sulfamide configuration. A selected sulfamide was profiled in vitro and in vivo and displayed a promising ADMET profile.

引用

页码：9567 / 9573

页数：7

共 50 条

[41] Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system
Suzuki, Yuko
Sano, Hideto
Mochizuki, Liina
Honkura, Naoki
Urano, Tetsumei
BLOOD ADVANCES, 2020, 4 (21) : 5501 - 5511
[42] Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation
Kim, P. Y. G.
Kim, P. Y.
Hoogendorn, H.
Giles, A. R.
Nesheim, M. E.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) : 1600 - 1602
[43] Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor
Ito, Yusuke
Noguchi, Kengo
Morishima, Yoshiyuki
Yamaguchi, Kyoji
BLOOD COAGULATION & FIBRINOLYSIS, 2018, 29 (03) : 314 - 321
[44] Activated thrombin activatable fibrinolysis inhibitor is a novel anti-metastatic factor in breast cancer
Bazzi, Zainab A.
Rudy, Deborah
Porter, Lisa A.
Cavallo-Medved, Dora
Boffa, Michael B.
CANCER RESEARCH, 2015, 75
[45] Thrombin-activatable fibrinolysis inhibitor and activated factor XII in patients with systemic lupus erythematosus
Ringwald, Juergen
Buettner, Stefanie
Zimmermann, Robert
Weisbach, Volker
Strasser, Erwin
Eckstein, Reinhold
THROMBOSIS RESEARCH, 2007, 119 (01) : 129 - 131
[46] The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet Disease and their association with thrombosis
Donmez, Ayhan
Aksu, Kenan
Aydin, Hakan
Keser, Gokhan
Cagirgan, Seckin
Doganavsargil, Eker
Tombuloglu, Murat
THROMBOSIS RESEARCH, 2010, 126 (03) : 207 - 210
[47] Synthesis and evaluation of imidazole acetic acid inhibitors of thrombin-activatable fibrinolysis inhibitor (TAFI).
Stauffer, SR
Barrow, JC
Nanterment, PG
Ngo, PL
Steinbeiser, M
Mao, SS
Carroll, S
Cooper, C
Colussi, D
Cook, JJ
Tiller, P
Fernandez-Metzler, C
Rose, MJ
Wong, B
McMasters, DR
Vacca, JP
Selnick, HG
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U205 - U205
[48] The Kinetics of Activated Thrombin-Activatable Fibrinolysis Inhibitor with Respect to Plasminogen Binding Site Removal From Fibrin Degradation Products
Foley, Jonathan H.
Nesheim, Michael E.
BLOOD, 2009, 114 (22) : 1234 - 1235
[49] DS-1040 an Inhibitor of the Activated Thrombin Activatable Fibrinolysis Inhibitor Improves Behavior in Embolized Rabbits.
Lapchak, Paul A.
Boitano, Paul D.
Noguchi, Kengo
STROKE, 2016, 47
[50] Binding of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) to Plasminogen May Play a Role in the Fibrinolytic Pathway
An, Seong Soo A.
Suh, Inbum
BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2008, 29 (11): : 2209 - 2214

← 1 2 3 4 5 →